Subjective Vertical Position Allows Prediction of Postural Deterioration in Patients with Parkinson’s Disease

Kyohei Mikami,† 1 Makoto Shiraishi,‡ 2 and Tsutomu Kamo 3

1Department of Rehabilitation, Noborito Neurology Clinic, Kawasaki, Kanagawa, Japan
2Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
3Department of Neurology, Noborito Neurology Clinic, Kawasaki, Kanagawa, Japan

Correspondence should be addressed to Kyohei Mikami; kyo.mikami@gmail.com

Received 24 October 2018; Revised 27 February 2019; Accepted 18 March 2019; Published 2 April 2019

Background. We believe that, in patients with Parkinson’s disease (PD), a forward-directed increase in the subjective vertical position (SV) leads to prolonged worsening of forward flexion of the trunk (FFT) mainly because the body adjusts to the SV. We conducted a study to clarify the relation between the SV angle, FFT angle, and various other clinical measures by comparing baseline values against values obtained 1 year later.

Methods. A total of 39 PD patients (mean age, 71.9 ± 10.1 years; disease duration, 7.2 ± 5.4 years; modified Hoehn & Yahr (mH&Y) score, 2.6 ± 0.7) were enrolled. The Unified Parkinson’s Disease Rating Scale score, Mini-Mental State Examination (MMSE) score, mH&Y score, FFT angle, SV angle, and levodopa-equivalent dose (LED) were assessed at the time of enrollment (baseline evaluation) and 1 year later.

Results. Eighteen patients (46%) complied with the protocol and completed the study. Significant increases were observed in the 1-year SV angle (p = 0.02), MMSE score (p = 0.008), and LED (p = 0.001) compared to baseline values. Correlation was observed between the baseline SV angle and baseline and 1-year FFT angles (r = 0.64, p = 0.008 and r = 0.58, p = 0.012, respectively) and between the 1-year SV angle and 1-year FFT angle (r = 0.63, p = 0.005). Conclusion. Our data suggest that the SV contributes to increased FFT.

1. Introduction

As a common clinical symptom in patients with Parkinson’s disease (PD), forward flexion of the trunk (FFT) becomes more severe as the disease severity increases [1, 2], and it is an important factor in gait disorder, decreased quality of life, and patients’ inability to perform activities of daily living [3–5]. However, FFT is resistant to anti-Parkinson drugs [6, 7], and although the efficacies of botulinum toxin [8, 9], deep brain stimulation [10, 11], and rehabilitation [12, 13] are being tested, effective treatment remains elusive. This difficulty stems from the lack of a clear definition of the disease state [14] due to its multifactorial etiology, with contributing factors that include rigidity [15], dystonia [16], drug indocement [17], and proprioceptive integration [18] and vestibular sensation deficits [19]. On investigating the relationship between FFT and PD patients’ subjective vertical position (SV) [20], we found larger SV angles among patients with larger FFT angles. Conversely, large SV angles were also observed in some PD patients with mild or moderate FFT, indicating that the SV angle is not determined by severity of the FFT. On the basis of these findings, we hypothesized that a forward-directed increase in the SV is a factor in long-term exacerbation of FFT. The present study aimed to compare SV and FFT angles obtained upon patients’ enrollment (baseline measurements) and 1 year later to clarify the relationship between SV and various clinical markers and increase in the FFT angle at 1 year.

2. Methods

2.1. Study Patients. A total of 39 individuals with PD (17 men, 22 women aged 71.9 ± 10.1 years) who were outpatients at our facility and met the selection criteria were enrolled in the study. These patients were selected from among 99 outpatients with PD. Inclusion criteria comprised (1) a diagnosis of clinically probable or clinically established PD (according to the International Parkinson and Movement Disorder Society Diagnostic Criteria, 2015 [21]); (2) regular
follow-up examinations; (3) consent to and participation in PD assessment during routine care; (4) stages I–IV on the modified Hoehn & Yahr (mH&Y) Scale; (5) confirmation of the ON state at the time of observation; (6) a Mini-Mental State Examination (MMSE) score ≥24; (7) no predictable wearing off lasting for more than half of the day and no sudden, unpredictable wearing off (Unified Parkinson’s Disease Rating Scale (UPDRS) Item 39 score ≤2); (8) no psychiatric symptoms, such as severe hallucinations or delusions, that inhibit normal daily living activities (UPDRS Item 2 score <3); (9) ability to maintain a standing position; and (10) range of motion (ROM) in trunk extension ≥5°. Patients in whom PD symptoms, including postural abnormality, exacerbated markedly within 1 week were excluded.

The postural and clinical assessments applied in the present study were those conducted for all patients undergoing rehabilitation therapy at our facility and are aimed at evaluating the effectiveness of the therapy. The therapy included a general exercise regimen for PD patients comprising 15 minutes of aerobic exercise and 60 minutes of muscle stretching and strengthening exercises performed once a week to once every 2 weeks. Written informed consent was obtained from patients who met the inclusion criteria based on thorough verbal and written explanations of the study objective and use of the data. Use of the data was approved by the Ethics Committee of the Japan Primary Care Association (2017-006).

2.2. Postural Assessment Items. Posture was assessed by measuring FFT and SV angles with the use of free image analysis software (Image J; https://imagej.nih.gov/ij/index.html). Still lateral-view images of the patient (90°) were obtained at the level of the iliac crest with the use of a 10.1-megapixel digital camera (Panasonic DMC-LZ10) positioned at a distance of 2 m. On the basis of the Japanese Association of Rehabilitation Medicine’s joint ROM measurement method, reflective markers were attached to show the positions of the seventh cervical (C7) and fifth lumbar (L5) spinous processes as analysis landmarks. The FFT angle is determined as follows: the patients stand with eyes open, and the angle between the vertical axis, defined as the line passing vertically through L5 to the floor, and the forward flexion axis, defined as the line connecting C7 and L5 (Figure 1(a)) is measured. The SV angle is then measured as follows: the patient stands with eyes closed but bending forward at the waist so that there is a 45-degree angle between the vertical line drawn on the wall behind the patient and the patient’s spine at C7 (Figure 1(b), left panel). The patient’s upper body is then passively moved from 45° to 0° in 5 seconds, and the patient is asked to signal when perceiving that he/she has reached a vertical position (Figure 1(b), right panel). At this point, movement is stopped, and a still image is taken. The procedure is repeated three times, the SV angle is measured three times, and the mean value is taken as the patient’s SV angle.

2.3. Clinical Assessment Items. Data including patients’ age, disease duration, and anti-Parkinson drug dosage, including both levodopa-equivalent dose (LED) and use of dopamine agonists, were recorded [22]. Severity of the PD was assessed according to the mH&Y Scale and UPDRS (UPDRS total score). In addition, UPDRS parts I, II, III, and IV (UPDRS I–IV) were used for assessment of cognitive function, activities of daily living, motor function, and treatment complications, respectively.

2.4. Statistical Analyses. Data are presented as mean ± standard deviation. Comparisons between baseline and 1-year assessment items were performed by means of the Wilcoxon signed-rank test. Receiver operating characteristic (ROC) analysis was used to test the ability of items showing a significant increase at 1 year to accurately predict increase in the FFT angle at 1 year.

Relations between baseline assessment items, between 1-year assessment items, and between baseline assessment items and the 1-year FFT angle were evaluated on the basis of Spearman’s rank correlation coefficient. Multiple regression analysis was performed to investigate the relationship between baseline assessment items and 1-year SV angle and 1-year FFT angle, with baseline FFT angle, baseline SV angle, age, and disease duration used as independent variables. All statistical analyses were performed with SPSS version 21 statistical software (IBM SPSS Statistics for Windows; IBM Corp, Armonk, NY), and significance was set at p < 0.05.

3. Results

3.1. Patient Characteristics. In total, 18 patients (9 men, 9 women; age, 70.3 ± 6.7 years; disease duration, 8.6 ± 6.6 years) recruited between September and October 2015 completed the study, having undergone assessments at the time of enrollment and 1 year later (Table 1). The 1-year assessments could not be performed in 21 patients because of a change in the primary doctor due to hospitalization, admission to a residential facility, or a similar circumstance (n = 10); difficulty maintaining a standing position due to motor impairment (n = 5); ROM in trunk extension ≤5° due to low back pain (n = 4); or difficulty understanding instructions due to mental or cognitive impairment (n = 2).

3.2. Relations between Baseline Assessment Items. The baseline variables did not differ significantly between the 18 patients who completed the study and 21 patients who did not complete the study (Table 2). Among patients who did complete the study, significant correlation was found between the following baseline assessment items: FFT angle and SV angle (r = 0.58, p = 0.012); mH&Y score and disease duration (r = −0.51, p = 0.03); UPDRS II score and UPDRS III score (r = 0.77, p < 0.0001) and UPDRS total score (r = 0.89, p < 0.0001); and UPDRS III score and UPDRS IV score (r = −0.48, p = 0.045) and UPDRS total score (r = 0.91, p < 0.0001). No significant correlation was observed between age, MMSE score, UPDRS I score, or LED and any of the other items assessed (Table 3).
Table 2: Baseline characteristics of patients who underwent 1 year of follow-up and those who did not.

|                          | Patients who were followed up for 1 year (n = 18) | Patients who were not followed up for 1 year (n = 21) | p value |
|--------------------------|--------------------------------------------------|-------------------------------------------------------|---------|
| Age (years)              | 70.3 ± 6.7                                       | 73.2 ± 11.6                                           | 0.35    |
| Sex (male/female)        | 9/9                                               | 8/13                                                  | 0.45    |
| Disease duration (years) | 8.6 ± 6.6                                        | 6.0 ± 3.5                                             | 0.28    |
| MMSE                     | 28.3 ± 1.7                                       | 27.3 ± 2.2                                            | 0.22    |
| mH&Y                     | 2.5 ± 0.6                                        | 2.6 ± 0.8                                             | 0.90    |
| FFT angle (°)            | 12.8 ± 12.9                                      | 8.0 ± 15.0                                            | 0.23    |
| SV angle (°)             | 6.0 ± 9.8                                        | 4.5 ± 9.9                                             | 0.77    |
| UPDRS I                  | 2.2 ± 1.6                                        | 2.0 ± 1.2                                             | 0.92    |
| UPDRS II                 | 8.6 ± 6.0                                        | 7.3 ± 5.2                                             | 0.64    |
| UPDRS III                | 14.2 ± 9.4                                       | 16.2 ± 8.9                                            | 0.50    |
| UPDRS IV                 | 2.4 ± 2.8                                        | 2.4 ± 2.2                                             | 0.69    |
| UPDRS total              | 27.3 ± 13.7                                      | 28.0 ± 13.9                                           | 0.88    |
| LED (mg/day)             | 636 ± 199.4                                      | 749.0 ± 349.5                                         | 0.25    |

Table 1: Characteristics of the study patients (n = 18).

Mean ± SD values or numbers of patients are shown. mH&Y, modified Hoehn & Yahr Scale; MMSE, Mini-Mental State Examination; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson’s Disease Rating Scale; LED, levodopa-equivalent dose.

Parkinson’s Disease
Table 3: Baseline variables and relationships between them.

|                          | Mean | Range | Age (years) | Disease duration (years) | MMSE | mH&Y | FFT angle (°) | SV angle (°) | UPDRS I | UPDRS II | UPDRS III | UPDRS IV | UPDRS total | LED (mg/day) |
|--------------------------|------|-------|-------------|--------------------------|------|------|---------------|-----------|---------|----------|-----------|----------|-------------|--------------|
| Age (years)              | 70.3 | 55–83 |             |                          |      |      |               |            |         |          |           |          |             |              |
| Disease duration (years) | 8.6  | 1–26  | −0.428      |                          |      |      |               |            |         |          |           |          |             |              |
| MMSE score               | 28.3 | 25–30 | −0.386      | 0.074                    |      |      |               |            |         |          |           |          |             |              |
| mH&Y score               | 2.5  | 1–3.5 | 0.119       | −0.508*                  | 0.081|      |               |            |         |          |           |          |             |              |
| FFT angle (°)            | 12.8 | −11–45| −0.018      | 0.343                    | −0.125|−0.404|               |            |         |          |           |          |             |              |
| SV angle (°)             | 6.0  | −9.3–35.7 | −0.187 | 0.219 | 0.177 | −0.096 | 0.580* |           |         |          |           |          |             |              |
| UPDRS I                  | 2.2  | 0–5   | 0.217       | 0.068                    | 0.088| 0.127 | −0.007       | 0.227     |         |          |           |          |             |              |
| UPDRS II                 | 8.6  | 1–20  | 0.250       | −0.125                   | −0.094|−0.136| 0.264        | 0.351     | 0.292   |          |           |          |             |              |
| UPDRS III                | 14.2 | 2–30  | 0.338       | −0.373                   | −0.309|−0.083| 0.032        | 0.171     | 0.139   | 0.771*   |           |          |             |              |
| UPDRS IV                 | 2.4  | 0–11  | −0.221      | 0.449                    | 0.122| 0.138| −0.169       | −0.236    | −0.412  | −0.334   | −0.478*   |           |             |              |
| UPDRS total              | 27.3 | 9–50  | 0.260       | −0.091                   | −0.292|−0.208| 0.142        | 0.214     | 0.254   | 0.889*   | 0.914*    | −0.293   |             |              |
| LED (mg/day)             | 635  | 333–1124 | −0.297 | 0.233 | 0.085 | −0.243 | −0.075 | 0.149 | −0.276 | 0.160 | −0.065 | 0.253 | 0.034 |

Values shown are Spearman correlation coefficients, unless otherwise indicated. MMSE, Mini-Mental State Examination; mH&Y Scale, modified Hoehn & Yahr Scale; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson's Disease Rating Scale; LED, levodopa-equivalent dose. * p < 0.05.
3.3. Changes in Assessment Items at 1 Year and Results of Correlation Analysis. Changes in assessment items at 1 year for the 18 patients who were included in the study are shown in Table 4. Compared to baseline values, significant increases were observed in 1-year SV angle ($p = 0.02$), MMSE score ($p = 0.008$), and LED ($p = 0.001$). No difference was observed in the mH&Y score, UPDRS III score, UPDRS total score, FFT angle, or dopamine agonist use. Changes in 1-year SV angle, MMSE score, and LED did not correlate significantly with disease duration. The area under the ROC curve showed the prediction accuracies of the baseline MMSE score, SV angle, and LED for an increase in the 1-year FFT angle to be 0.400 (95% confidence interval (CI), 0.122–0.678), 0.377 (95% CI, 0.039–0.715), and 0.677 (95% CI, 0.432–0.922), respectively.

Significant correlation was observed for the following 1-year assessment items: FFT angle with SV angle ($r = 0.64, p = 0.008$) and UPDRS I score ($r = 0.53, p = 0.024$); UPDRS I score with UPDRS II ($r = 0.64, p = 0.004$), UPDRS III ($r = 0.56, p = 0.016$), and UPDRS total ($r = 0.69, p < 0.001$) scores; UPDRS II score with UPDRS III ($r = 0.62, p = 0.006$) and UPDRS total ($r = 0.82, p < 0.001$) scores; UPDRS III score with UPDRS total score ($r = 0.93, p < 0.001$); and UPDRS IV score with disease duration ($r = 0.72, p = 0.001$). No significant correlation was observed between age, MMSE score, mH&Y score, or LED and any of the other 1-year assessment items (Table 5).

3.4. Relationships between Baseline and 1-Year Follow-Up Assessment Items. The SV angle was the only baseline assessment item that correlated significantly with the 1-year FFT angle ($r = 0.63, p = 0.005$; Figure 2(a)). No significant correlation was observed between the 1-year FFT angle and the baseline FFT angle (Figure 2(b)), baseline LED (Figure 2(c)), baseline UPDRS part III score (Figure 2(d)), age, disease duration, mH&Y score, MMSE score, UPDRS I–II and IV scores, or UPDRS total score. In addition, no significant correlation was found between change in the SV angle (4.9 ± 7.9) and change in the FFT angle (1.1 ± 9.0) at 1 year ($r = 0.29$).

4. Discussion

On the basis of the hypothesis that a forward-directed increase in the SV is an exacerbating factor for FFT in patients with PD, changes in clinical markers, including the SV angle and FFT angle, were investigated after 1 year. Positive correlation was observed between the SV angle and the FFT angle, both at baseline and 1 year later, indicating a relationship between SV and FFT, as previously reported [20]. No significant change was found in the FFT angle after 1 year, and no significant correlation was found between the baseline and 1-year FFT angles, indicating that the baseline FFT angle is not a contributing factor to the change in FFT angle at 1 year.

Generally, when a patient’s bending posture worsens, the patient’s disease status has deteriorated, as evidenced by an increase in other signs and symptoms, but, notably, FFT has been shown not to worsen markedly in patients who maintain a high level of physical activity [23]. Our study patients’ UPDRS and mH&Y scores did not change significantly, suggesting that their motor function deteriorated only mildly during the observation period. These patients were undergoing rehabilitation therapy regularly, and this might have contributed to what turned out to be a rather modest change in FFT. Although rehabilitation therapy has been reported to positively affect FFT [24, 25], no such effect on SV (either from physical activity or rehabilitation therapy) has been reported. The SV of PD patients may worsen as a result of deterioration of patients’ intrinsic sense and sensory integration [18, 26, 27] or of abnormal multisensory integration [28, 29] in the basal ganglia. That is, in the case of FFT and SV, it is argued that the difference in the degree of exacerbation of the FFT and SV distortion is reflected in the difference in change in the measured values. As a result, correlation between the SV angle and FFT angle persists, and SV distortion occurs prior to a negative change in FFT and may signal exacerbation of FFT. In addition, increased SV distortion along with increased FFT is thought to parallel prolonged physical inactivity in the absence of rehabilitation therapy. Multiple logistic regression analysis showed the SV angle to be a factor contributing to the 1-year FFT angle. The present findings support our previously reported findings that patients with a large FFT angle also have a large SV angle and also support our hypothesis that the SV distortion is an exacerbating factor for FFT [20]. Although no previous studies have directly investigated the effects of SV on FFT, Vaugoyeau et al. reported that proprioceptive integration deficits contribute to PD patients’ difficulty in maintaining a vertical position [18].

Not only a significant increase in the SV angle but also a significant 1.4-point decrease in the MMSE score was observed after 1 year. The prevalence of cognitive impairment after 10 and 20 years of PD is reported to be 46% [30] and 83% [31], respectively. The MMSE is used in PD patients to screen for cognitive impairment rather than to show specific cognitive deficits or executive dysfunction.

| Table 4: Clinical assessment values upon enrollment (baseline) and after 1 year of follow-up. | Baseline | 1 year | $p$ value |
|---|---|---|---|
| mH&Y score | 2.5 ± 0.6 | 2.5 ± 0.7 | 0.7 |
| UPDRS I | 2.2 ± 1.6 | 2.4 ± 1.7 | 0.7 |
| UPDRS II | 8.6 ± 6.0 | 6.7 ± 3.9 | 0.3 |
| UPDRS III | 14.2 ± 9.4 | 16.5 ± 9.9 | 0.4 |
| UPDRS IV | 2.4 ± 2.8 | 2.2 ± 2.1 | 0.7 |
| UPDRS total | 27.3 ± 13.7 | 27.8 ± 13.8 | 0.9 |
| MMSE | 28.3 ± 1.7 | 26.9 ± 2.3 | 0.008 |
| FFT angle (°) | 12.8 ± 12.9 | 13.9 ± 9.8 | 0.6 |
| SV angle (°) | 6.0 ± 9.8 | 11.0 ± 6.1 | 0.02 |
| LED (mg/day) | 636 ± 199.4 | 939 ± 368.4 | 0.001 |

Dopamine agonist (%) 100 94.4 0.5

Mean ± SD values are shown. mH&Y Scale, modified Hoehn & Yahr Scale; MMSE, Mini-Mental State Examination; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson’s Disease Rating Scale; LED, levodopa-equivalent dose.
Table 5: Relationships between study variables after 1 year of follow-up.

|                       | Mean | Range    | Disease duration (years) | MMSE | mH&Y | FFT angle (°) | SV angle (°) | UPDRS I | UPDRS II | UPDRS III | UPDRS IV | UPDRS total | LED (mg/day) |
|-----------------------|------|----------|--------------------------|------|------|--------------|-------------|---------|----------|-----------|----------|-------------|--------------|
| Age (years)           | 71.3 | 56–84    |                          |      |      |              |             |         |          |           |          |             |              |
| Disease duration (years) | 9.8  | 2–28    |                          |      |      |              |             |         |          |           |          |             |              |
| MMSE                  | 26.9 | 21–30   | −0.286                   | 0.286| 0.149| 0.198        | 0.223       |         |          |           |          |             |              |
| mH&Y                  | 2.5  | 1–4     | −0.101                   | 0.414| 0.223|              |             |         |          |           |          |             |              |
| FFT angle (°)         | 13.9 | 5–38    | −0.227                   | 0.218| 0.114| −0.181       | 0.227       |         |          |           |          |             |              |
| SV angle (°)          | 11.0 | 3–23    | −0.359                   | 0.139| 0.012| 0.198        | 0.639       | 0.060   |          |           |          |             |              |
| UPDRS I               | 2.4  | 0–5     | −0.057                   | 0.113| 0.237| −0.529       |             |         |          |           |          |             |              |
| UPDRS II              | 6.7  | 0–14    | 0.008                    | 0.027| 0.164| −0.383       | 0.064       |         | 0.639*   |           |          |             |              |
| UPDRS III             | 16.5 | 3–35    | 0.128                    | 0.057| 0.012| −0.270       | 0.192       |         |          | 0.561*   | 0.624**  |             |              |
| UPDRS IV              | 2.2  | 0–6     | −0.223                   | 0.722| 0.151| −0.199       | 0.179       |         | 0.105    | −0.196   |          |             |              |
| UPDRS total           | 27.8 | 7–49    | 0.012                    | 0.155| 0.381| 0.192        | 0.928*      | 0.032   |          |           |          |             |              |
| LED (mg/day)          | 938  | 425–1849| 0.109                    | 0.366| 0.303| −0.284       | 0.088       | −0.035  | −0.163   | 0.223    | −0.103   | 0.461       | 0.043        |

Values shown are Spearman correlation coefficients, unless otherwise indicated. MMSE, Mini-Mental State Examination; mH&Y Scale, modified Hoehn & Yahr Scale; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson’s Disease Rating Scale; LED, levodopa-equivalent dose. * p < 0.05.
Although patients’ MMSE scores decreased mildly by 1.4 points along with the change in posture, we found no correlation between patients’ MMSE scores and the SV angle or FFT angle, and thus the MMSE score cannot be used as an index to assess posture abnormality. Cognitive function based on somatic [18] and vestibular [19] sensation reportedly plays a role in perception of the vertical position of the body [33]. Wuth, perception of the vertical position as represented by the SV angle relies on cognitive function based on processing of sensory information rather than that assessed by the MMSE. Broader assessment of cognitive is needed to clarify the kinds of cognitive function that affect perception of the vertical position of the body as represented by the SV angle in PD patients. In this study, the patients’ LED was significantly increased at 1 year, but because FFT did not worsen significantly and actually improved in some patients, we need to further verify the significance of SV.

The limitations of the present study include the small patient group (n = 18). Furthermore, patients with severe PD, such as those with M&H stage V disease, with an MMSE score <24, with severe psychiatric symptoms such as hallucinations or delusions, or with severe wearing off, were excluded; therefore, further investigation is required to determine the effects of increasing symptom severity on FFT. No countermeasure has been developed to prevent alterations in the SV. Such a countermeasure is needed, and we believe that FFT should be evaluated in patients yearly, with a view toward maintenance of the SV. Finally, the influence of rehabilitation therapy could not be ruled out because there was no significant change between the baseline and 1-year follow-up measures of FFT.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Disclosure**

A small part of this paper was presented in a poster at the 23rd World Congress of Neurology in Kyoto, Japan, in 2017. The authors used the same title for the poster presentation.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest regarding the publication of this article.
Acknowledgments

The authors thank Ryoma Aoki and Yumiko Ishiguro, occupational therapists of the Department of Rehabilitation, Noborito Neurology Clinic, for their assistance in data collection. The authors also thank Tina Tajima, Professor of the Research Institute of Medical Education, St. Marianna University School of Medicine, for meticulous English editing.

References

[1] N. G. Margraf, A. Wrede, A. Rohr et al., “Camptocormia in idiopathic Parkinson’s disease: a focal myopathy of the paravertebral muscles,” Movement Disorders, vol. 25, no. 5, pp. 542–551, 2010.

[2] F. Bloch, J. L. Houeto, S. Tezenas du Montcel et al., “Parkinson’s disease with camptocormia,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 77, no. 11, pp. 1223–1228, 2006.

[3] R. Ashour and J. Jankovic, “Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy,” Movement Disorders, vol. 21, no. 11, pp. 1856–1863, 2006.

[4] D. Tiple, G. Fabbrini, C. Colosimo et al., “Camptocormia in Parkinson disease: an epidemiological and clinical study,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 80, no. 2, pp. 145–149, 2009.

[5] K. Mikami, M. Shiraishi, and T. Kamo, “Effect of abnormal posture on quality of life in patients with Parkinson’s disease,” Advances in Parkinson’s Disease, vol. 5, no. 2, pp. 7–14, 2016.

[6] S. N. Azher and J. Jankovic, “Camptocormia: pathogenesis, classification, and response to therapy,” Neurology, vol. 65, no. 3, pp. 355–359, 2005.

[7] R. Djaldetti, R. Mosberg-Galili, H. Sroka, D. Merims, and E. Melamed, “Camptocormia (bent spine) in patients with Parkinson’s disease-characterization and possible pathogenesis of an unusual phenomenon,” Movement Disorders, vol. 14, no. 3, pp. 443–447, 1999.

[8] K. L. Bertram, P. Stirpe, and C. Colosimo, “Treatment of camptocormia with botulinum toxin,” Toxicon, vol. 107, pp. 148–153, 2015.

[9] S. Wijemanne and J. Jimenez-Shahed, “Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle,” Parkinsonism & Related Disorders, vol. 20, no. 10, pp. 1106–1107, 2014.

[10] H.-H. Capelle, C. Schrader, C. Blahak et al., “Deep brain stimulation for camptocormia in dystonia and Parkinson’s disease,” Journal of Neurology, vol. 258, no. 1, pp. 96–103, 2010.

[11] C. D. Upadhyaya, S. Berven, and P. V. Mummaneni, “Spondylolisthesis following a pedicle subtraction osteotomy,” Neurosurgical Focus, vol. 28, no. 3, p. E16, 2010.

[12] B. R. Bloem, D. J. Beckley, and J. G. van Dijk, “Are automatic postural responses in patients with Parkinson’s disease abnormal due to their stooped posture?,” Experimental Brain Research, vol. 124, no. 4, pp. 481–488, 1999.

[13] M. Sèze, A. Creuzé, M. Sèze, and J. Mazaux, “An orthosis and physiotherapy programme for camptocormia: a prospective case study,” Journal of Rehabilitation Medicine, vol. 40, no. 9, pp. 761–765, 2008.

[14] K. M. Doherty, B. P. van de Warrenburg, M. C. Peralta et al., “Postural deformities in Parkinson’s disease,” The Lancet Neurology, vol. 10, no. 6, pp. 538–549, 2011.

[15] W. G. Wright, V. S. Gurfinkel, J. Nutt, F. B. Horak, and P. J. Cordo, “Axial hypertonicity in Parkinson’s disease: direct measurements of trunk and hip torque,” Experimental Neurology, vol. 208, no. 1, pp. 38–46, 2007.

[16] K. L. Bertram and C. Colosimo, “Camptocormia may be myopathic or dystonic,” Muscle & Nerve, vol. 54, no. 2, p. 343, 2016.

[17] A. Cannas, P. Solla, G. L. Floris, G. Borghero, P. Tacconi, and A. Spissu, “Reversible pisa syndrome in Parkinson’s disease during treatment with pergolide,” Clinical Neuropharmacology, vol. 28, no. 5, p. 252, 2005.

[18] M. Vaugoyeau and J.-P. Azulay, “Role of sensory information in the control of postural orientation in Parkinson’s disease,” Journal of the Neurological Sciences, vol. 289, no. 1-2, pp. 66–68, 2010.

[19] C. Vitale, V. Marcelli, T. Furia et al., “Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion,” Movement Disorders, vol. 26, no. 8, pp. 1458–1463, 2011.

[20] K. Mikami, M. Shiraishi, T. Kawasaki, and T. Kamo, “Forward flexion of trunk in Parkinson’s disease patients is affected by subjective vertical position,” PLoS One, vol. 12, no. 7, Article ID e0181210, 2017.

[21] R. B. Postuma, D. Berg, M. Stern et al., “MDS clinical diagnostic criteria for Parkinson’s disease,” Movement Disorders, vol. 30, no. 12, pp. 1591–1601, 2015.

[22] C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010.

[23] A. Khlebtovskyy, R. Djaldetti, Y. Rodity et al., “Progression of postural changes in Parkinson’s disease: quantitative assessment,” Journal of Neurology, vol. 264, no. 4, pp. 675–683, 2017.

[24] M. Morrone, S. Miccinilli, M. Bravi et al., “Perceptive re habilitation and trunk posture alignment in patients with Parkinson disease: a single blind randomized controlled trial,” European Journal of Physical and Rehabilitation Medicine, vol. 52, pp. 799–809, 2016.

[25] D. Volpe, M. G. Giantin, P. Manuela et al., “Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson’s disease: a randomized controlled pilot study,” Clinical Rehabilitation, vol. 31, no. 8, pp. 1107–1115, 2017.

[26] J. V. Jacobs and F. B. Horak, “Abnormal proprioceptive-motor integration contributes to hypometric postural responses of subjects with Parkinson’s disease,” Neurosciences, vol. 141, no. 2, pp. 999–1009, 2006.

[27] C. Ding, C. J. Palmer, J. Hohwy et al., “Parkinson’s disease alters multisensory perception: insights from the ‘Rubber Hand Illusion,’” Neuropsychologia, vol. 97, pp. 38–45, 2017.

[28] A. Nagy, G. Eördögh, Z. Paróczy, Z. Márkus, and G. Benedek, “Multisensory integration in the basal ganglia,” European Journal of Neuroscience, vol. 24, no. 3, pp. 917–924, 2006.

[29] R. Reig and G. Silberberg, “Multisensory integration in the mouse striatum,” Neuron, vol. 83, no. 5, pp. 1200–1212, 2014.

[30] C. H. Williams-Gray, S. L. Mason, J. R. Evans et al., “The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 84, no. 11, pp. 1258–1264, 2013.

[31] M. A. Hely, W. G. J. Reid, M. A. Adena, G. M. Halliday, and J. G. L. Morris, “The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years,” Movement Disorders, vol. 23, no. 6, pp. 837–844, 2008.
[32] B. Dubois, D. Burn, C. Goetz et al., “Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force,” *Movement Disorders*, vol. 22, no. 16, pp. 2314–2324, 2007.

[33] G. Barbieri, A.-S. Gissot, and D. Pérennou, “Ageing of the postural vertical,” *Age*, vol. 32, no. 1, pp. 51–60, 2010.